10-Q: Positron Corp Q3 2026: Net Loss Widens, Going Concern Doubt

Positron Corporation reported a net loss of $3.17 million for the nine months ended September 30, 2026, with significant going concern risks despite efforts to secure financing and expand market reach.

Summary

• Positron Corporation reported a net loss of $3,171,151 for the nine months ended September 30, 2026, an improvement from the $3,702,063 loss in the same period of 2025.
• Revenues decreased slightly to $325,489 for the nine months ended September 30, 2026, from $350,452 in the prior year period.
• Cost of sales increased significantly by 31.4% to $1,506,659 for the nine months ended September 30, 2026, impacting gross loss.
• General and administrative expenses decreased by 32.0% to $1,905,089 for the nine months ended September 30, 2026, primarily due to a one-time NRE fee in the prior year.
• The company has a working capital deficiency of $1,200,539 as of September 30, 2026, and cash on hand of $1,925,653.
• Substantial doubt exists regarding the company's ability to continue as a going concern within the next twelve months.
• The company is pursuing strategic plans including expanding its PET-CT system into oncology and pursuing an up-listing to a more prominent exchange.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the company's continued net losses, significant working capital deficiency, and substantial doubt about its ability to continue as a going concern, despite some strategic initiatives.

Positives

• Net loss decreased by $530,912 for the nine months ended September 30, 2026, compared to the same period in 2025.
• General and administrative expenses decreased by $898,169 for the nine months ended September 30, 2026, due to a significant one-time expense in the prior year.
• The company has $1,925,653 in cash and cash equivalents as of September 30, 2026.
• A $2,000,000 revolving line of credit is available, though no advances had been drawn as of September 30, 2026.
• Strategic plans include expanding into the oncology market and pursuing an up-listing to a more prominent exchange.

Negatives

• The company reported a net loss of $3,171,151 for the nine months ended September 30, 2026.
• Revenues decreased by 7.1% to $325,489 for the nine months ended September 30, 2026.
• Cost of sales increased by 31.4% to $1,506,659 for the nine months ended September 30, 2026.
• The company has a working capital deficiency of $1,200,539 as of September 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within the twelve-month period subsequent to the issuance of these financial statements.
• Notes payable to related parties increased significantly to $2,362,571 as of September 30, 2026.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern within the twelve-month period subsequent to the date that these financial statements are issued.
• The company does not expect to generate sufficient revenues and positive cash flows from operations to meet its current obligations.
• The company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain.
• The timing and ultimate determination of FDA clearance for the next-generation PET/CT 4D system remain subject to regulatory review and are considered reasonably possible but not probable.
• The company operates in a highly competitive industry subject to intense market dynamics, shifting consumer demand, and economic fluctuations.
• Macroeconomic conditions such as economic downturns, inflationary pressures, interest rate changes, global tariff policy, and geopolitical risks may impact consumer purchasing behavior and the company's revenue streams.
• Pricing volatility, supply chain disruptions, and competitive pricing pressures can lead to fluctuations in gross margins and profitability.

Future Outlook

The company plans to execute business operations more fully, expand its reach in nuclear cardiology with its PET-CT system, enter the oncology market with a faster, smaller, more economical solution, explore strategic partnership opportunities, and pursue an up-listing to a more prominent publicly reporting exchange.

Management Comments

• The Company does not expect to generate sufficient revenues and positive cash flows from operations sufficiently to meet its current obligations.
• However, the Company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain.
• Managements strategic plans include executing business operations more fully, expanding its reach within nuclear cardiology, entering the oncology market, exploring strategic and partnership opportunities, and pursuing an up-list to a more prominent publicly reporting exchange.

Industry Context

StockSavvy.ai notes that Positron Corporation operates in the medical technology sector, specifically focusing on PET and PET-CT imaging systems. The company's strategy involves expanding into the oncology market, a significant growth area within medical imaging, while also strengthening its position in cardiac PET imaging. The reliance on a strategic partner, Neusoft Medical Systems, for product development and manufacturing is a key aspect of its operational model.

Comparison to Industry Standards

• The company's revenue of $325,489 for the nine months ended September 30, 2026, is significantly lower than established players in the medical imaging market.
• The gross loss of $1,181,170 for the same period indicates challenges in cost management relative to revenue, which is a concern compared to industry benchmarks where gross margins are typically positive and substantial.
• The company's net loss of $3,171,151 for the nine months ended September 30, 2026, highlights a significant gap in profitability compared to mature medical technology companies.
• The substantial doubt about the company's ability to continue as a going concern is a critical deviation from industry standards for publicly traded companies.

Corporate Governance

Legal Proceedings

• The company is not aware of any legal proceedings to which it is a party or of which its property is the subject.
• The company is not aware of any litigation, pending litigation, or other transactions that require accrual or disclosure as of September 30, 2026, and December 31, 2025.

Related Party Transactions

• Notes payable to related parties totaled $2,362,571 as of September 30, 2026.
• A $2,000,000 revolving line of credit exists with a significant stockholder, with no advances drawn as of September 30, 2026.
• Warrants were issued to related parties in connection with financing transactions, including a line of credit and promissory notes.
• Deferred financing costs of $385,163 relate to the line of credit with a related party.
• Accrued interest payable to related parties was $474,236 as of September 30, 2026.

Stakeholder Impact

• Shareholders face continued dilution risk due to potential future capital raises and outstanding warrants.
• The going concern doubt poses a significant risk to shareholders, potentially leading to a loss of investment.
• Lenders and creditors face increased risk due to the company's working capital deficiency and net losses.
• Employees may face uncertainty regarding job security due to the company's financial precariousness.

Next Steps

• Execute business operations more fully during the current year.
• Expand its reach within nuclear cardiology with the launch of its PET-CT system.
• Enter the oncology market with its new PET-CT system.
• Explore and execute prospective strategic and partnership opportunities.
• Pursue to Up-List to a more prominent publicly reporting exchange.

Key Dates

Recommendation

The company's continued net losses, significant working capital deficiency, and substantial doubt about its ability to continue as a going concern, despite some strategic initiatives and improved G&A expenses, present a high-risk investment profile. The reliance on future capital raises and the uncertainty surrounding FDA clearance for key products further exacerbate these risks, making it a sell recommendation.

Keywords

PET-CT imaging systems, medical technology, cardiac PET imaging, oncology imaging, Neusoft Medical Systems, FDA clearance, revenue recognition, going concern